Potential Safety Concerns With Lixisenatide Despite Showing Slowed Motor Disability Progression in Phase 2 Trial for Early Parkinson Disease
The data is not yet there to proceed to prescribing,” Michael S. Okun, MD, national medical advisor for the Parkinson’s Foundation, told NeurologyLive®. “More importantly, the weight loss associated with GLP-1’s is not desirable in the majority of cases of Parkinson disease and the nausea and vomiting will not be a welcome…
